Keybank National Association OH Has $233,000 Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Keybank National Association OH increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVXFree Report) by 12.9% during the third quarter, HoldingsChannel.com reports. The fund owned 4,565 shares of the company’s stock after buying an additional 522 shares during the quarter. Keybank National Association OH’s holdings in Vaxcyte were worth $233,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. grew its position in Vaxcyte by 39.0% during the second quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock valued at $352,830,000 after buying an additional 1,983,223 shares during the period. Alliancebernstein L.P. grew its position in shares of Vaxcyte by 2,164.2% during the 2nd quarter. Alliancebernstein L.P. now owns 1,888,106 shares of the company’s stock valued at $94,292,000 after acquiring an additional 1,804,718 shares during the period. Fred Alger Management LLC purchased a new stake in shares of Vaxcyte during the 4th quarter worth approximately $42,066,000. Commodore Capital LP raised its holdings in shares of Vaxcyte by 407.5% in the 2nd quarter. Commodore Capital LP now owns 1,015,000 shares of the company’s stock worth $50,689,000 after purchasing an additional 815,000 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Vaxcyte by 13,673.8% in the first quarter. Franklin Resources Inc. now owns 716,239 shares of the company’s stock valued at $26,845,000 after purchasing an additional 711,039 shares during the last quarter.

Insider Buying and Selling at Vaxcyte

In related news, CEO Grant Pickering sold 30,000 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $66.03, for a total transaction of $1,980,900.00. Following the sale, the chief executive officer now owns 375,814 shares of the company’s stock, valued at $24,814,998.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Grant Pickering sold 30,000 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00. Following the transaction, the chief executive officer now directly owns 375,814 shares of the company’s stock, valued at $24,814,998.42. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $51.13, for a total transaction of $409,040.00. Following the sale, the chief financial officer now owns 79,474 shares of the company’s stock, valued at $4,063,505.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 145,566 shares of company stock valued at $9,002,817. 3.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PCVX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Vaxcyte in a research report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Bank of America lifted their target price on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Finally, Mizuho started coverage on shares of Vaxcyte in a research note on Thursday, December 7th. They set a “buy” rating and a $69.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $68.40.

Check Out Our Latest Stock Report on PCVX

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $74.14 on Friday. The company’s fifty day moving average price is $62.76 and its 200-day moving average price is $53.97. Vaxcyte, Inc. has a one year low of $34.11 and a one year high of $76.72.

Vaxcyte (NASDAQ:PCVXGet Free Report) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.07). Equities research analysts predict that Vaxcyte, Inc. will post -3.3 EPS for the current fiscal year.

Vaxcyte Profile

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Stories

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVXFree Report).

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.